Literature DB >> 25613677

The cryptophycins as potent payloads for antibody drug conjugates.

Vishal A Verma1, Thomas H Pillow2, Laura DePalatis2, Guangmin Li2, Gail Lewis Phillips2, Andrew G Polson2, Helga E Raab2, Susan Spencer2, Bing Zheng2.   

Abstract

The cryptophycins are a potent class of cytotoxic agents that were evaluated as antibody drug conjugate (ADC) payloads. Free cryptophycin analog 1 displayed cell activity an order of magnitude more potent than approved ADC payloads MMAE and DM1. This potency increase was also reflected in the activity of the cryptophycin ADCs, attached via a either cleavable or non-cleavable linker.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody drug conjugate; Cryptophycin

Mesh：

Substances：

Year:  2015        PMID： 25613677     DOI： 10.1016/j.bmcl.2014.12.070

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  17 in total

Review 1.  Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products.

Authors:  April L Risinger; Lin Du
Journal:  Nat Prod Rep       Date:  2019-11-25       Impact factor: 13.423

Review 2.  Strategies and challenges for the next generation of antibody-drug conjugates.

Authors:  Alain Beck; Liliane Goetsch; Charles Dumontet; Nathalie Corvaïa
Journal:  Nat Rev Drug Discov       Date:  2017-03-17       Impact factor: 84.694

Review 3.  Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment.

Authors:  David Howard; Jetzabel Garcia-Parra; Gareth D Healey; Cynthia Amakiri; Lavinia Margarit; Lewis W Francis; Deyarina Gonzalez; R Steven Conlan
Journal:  Interface Focus       Date:  2016-12-06       Impact factor: 3.906

4.  Biosynthetic Cyclization Catalysts for the Assembly of Peptide and Polyketide Natural Products.

Authors:  Maria L Adrover-Castellano; Jennifer J Schmidt; David H Sherman
Journal:  ChemCatChem       Date:  2021-01-28       Impact factor: 5.686

Review 5.  Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Authors:  Paul Malik; Colin Phipps; Andrea Edginton; Jonathan Blay
Journal:  Pharm Res       Date:  2017-09-18       Impact factor: 4.200

Review 6.  Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance.

Authors:  A R Kumar; M Murali; B Nair; K Pavithran; A R Devan; G K Pradeep; L R Nath
Journal:  Clin Transl Oncol       Date:  2021-09-30       Impact factor: 3.405

Review 7.  New Technologies Bloom Together for Bettering Cancer Drug Conjugates.

Authors:  Yiming Jin; Shahab Edalatian Zakeri; Raman Bahal; Andrew J Wiemer
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

8.  A Versatile Chemoenzymatic Synthesis for the Discovery of Potent Cryptophycin Analogs.

Authors:  Jennifer J Schmidt; Yogan Khatri; Scott I Brody; Catherine Zhu; Halina Pietraszkiewicz; Frederick A Valeriote; David H Sherman
Journal:  ACS Chem Biol       Date:  2020-02-03       Impact factor: 5.100

9.  Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.

Authors:  Alberto Dal Corso; Samuele Cazzamalli; Rémy Gébleux; Martin Mattarella; Dario Neri
Journal:  Bioconjug Chem       Date:  2017-07-06       Impact factor: 4.774

Review 10.  The Chemistry Behind ADCs.

Authors:  Vesela Kostova; Patrice Désos; Jérôme-Benoît Starck; Andras Kotschy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.